Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$102K Buy
17,092
+14,676
+607% +$104K ﹤0.01% 4998
2026
Q1
$24.5K Buy
2,416
+2
+0.1% +$19 ﹤0.01% 5270
2025
Q4
$16K Sell
2,414
-8
-0.3% -$91 ﹤0.01% 5249
2025
Q3
$31.3K Hold
2,422
﹤0.01% 5066
2025
Q2
$43.6K Hold
2,422
﹤0.01% 5015
2025
Q1
$52.4K Hold
2,422
﹤0.01% 4918
2024
Q4
$45.6K Sell
2,422
-75
-3% -$2.22K ﹤0.01% 4969
2024
Q3
$92.1K Hold
2,497
﹤0.01% 4683
2024
Q2
$61.1K Hold
2,497
﹤0.01% 4816
2024
Q1
$160K Hold
2,497
﹤0.01% 4639
2023
Q4
$309K Hold
2,497
﹤0.01% 4536
2023
Q3
$331K Sell
2,497
-3
-0.1% -$465 ﹤0.01% 4536
2023
Q2
$459K Sell
2,500
-410
-14% -$82K ﹤0.01% 4505
2023
Q1
$489K Sell
2,910
-271
-9% -$57K ﹤0.01% 4535
2022
Q4
$687K Buy
3,181
+20
+0.6% +$7.55K ﹤0.01% 4521
2022
Q3
$1.22M Sell
3,161
-39
-1% -$22.1K ﹤0.01% 4406
2022
Q2
$1.34M Sell
3,200
-7,287
-69% -$3.52M ﹤0.01% 4411
2022
Q1
$6.23M Sell
10,487
-149
-1% -$111K ﹤0.01% 3836
2021
Q4
$11.8M Buy
10,636
+184
+2% +$400K ﹤0.01% 3578
2021
Q3
$40.2M Buy
10,452
+128
+1% +$404K ﹤0.01% 2806
2021
Q2
$29.7M Buy
10,324
+648
+7% +$1.53M ﹤0.01% 3059
2021
Q1
$19.3M Buy
9,676
+5,569
+136% +$8.37M ﹤0.01% 3204
2020
Q4
$3.92M Buy
4,107
+177
+5% +$151K ﹤0.01% 3801
2020
Q3
$3.15M Buy
3,930
+82
+2% +$73K ﹤0.01% 3762
2020
Q2
$3.65M Buy
3,848
+3,700
+2,500% +$3.7M ﹤0.01% 3641
2020
Q1
$131K Buy
148
+6
+4% +$4.91K ﹤0.01% 4307
2019
Q4
$76K Buy
142
+32
+29% +$13.3K ﹤0.01% 4482
2019
Q3
$48K Sell
110
-6
-5% -$2.74K ﹤0.01% 4543
2019
Q2
$59K Buy
+116
New +$61.3K ﹤0.01% 4562
2018
Q2
Sell
-2
Closed -$1K 5060
2018
Q1
$1K Hold
2
﹤0.01% 4868
2017
Q4
$2K Hold
2
﹤0.01% 4815
2017
Q3
$4K Buy
+2
New +$4.14K ﹤0.01% 4766

Other funds holding PAVM

BlackRock's PAVM Position: Q2 2026 in Review

BlackRock increased its PAVmed (PAVM) stake by 607% in Q2 2026, buying an estimated $104K and bringing the position to 17,092 shares worth $102K. The position accounts for ﹤0.01% of the portfolio, ranked #4998.

BlackRock first reported a position in PAVM in Q3 2017 and has held it in 32 quarters since. The position peaked at $40.2M in Q3 2021. 3 funds tracked by Wall St. Rank hold PAVM as of Q2 2026.

  • BlackRock held 17,092 shares of PAVmed worth $102K as of Q2 2026.
  • BlackRock bought 14,676 PAVmed shares in Q2 2026, an estimated $104K.
  • PAVmed made up ﹤0.01% of BlackRock's portfolio in Q2 2026, its #4998 holding.
  • BlackRock first reported a position in PAVmed in Q3 2017 and has held it in 32 quarters since.
  • BlackRock's PAVmed position peaked at $40.2M in Q3 2021.
  • 3 funds tracked by Wall St. Rank held PAVmed as of Q2 2026.

Based on BlackRock's 13F filing for Q2 2026, filed 7 Aug 2026.